DrugPatentWatch Database Preview
Metuchen Pharms Company Profile
What is the competitive landscape for METUCHEN PHARMS, and when can generic versions of METUCHEN PHARMS drugs launch?
There are two US patents protecting METUCHEN PHARMS drugs.
There are fifty-three patent family members on METUCHEN PHARMS drugs in twenty-six countries and eight supplementary protection certificates in eight countries.
Summary for Metuchen Pharms
| International Patents: | 53 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Metuchen Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-001 | Apr 27, 2012 | RX | Yes | No | 6,656,935 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-003 | Apr 27, 2012 | RX | Yes | Yes | 7,501,409 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-001 | Apr 27, 2012 | RX | Yes | No | 7,501,409 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-002 | Apr 27, 2012 | RX | Yes | No | 7,501,409 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for METUCHEN PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 50 mg, 100 mg and 200 mg | ➤ Subscribe | 2016-04-27 |
Non-Orange Book US Patents for Metuchen Pharms
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,273,868 | Pyrazine derivatives | ➤ Try a Free Trial |
| 6,797,709 | Aromatic nitrogen-containing 6-membered cyclic compounds | ➤ Try a Free Trial |
| 7,220,736 | Pyrimidine compounds | ➤ Try a Free Trial |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Metuchen Pharms Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Bulgaria | 65453 | ➤ Try a Free Trial |
| Norway | 20021308 | ➤ Try a Free Trial |
| Mexico | PA03001958 | ➤ Try a Free Trial |
| Norway | 2013018 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Metuchen Pharms Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 6 | Finland | ➤ Try a Free Trial | |
| 249 | Luxembourg | ➤ Try a Free Trial | PRODUCT NAME: AVANAFIL |
| 2013000096 | Germany | ➤ Try a Free Trial | PRODUCT NAME: AVANAFIL UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/13/841 20130621 |
| 13/041 | Ireland | ➤ Try a Free Trial | PRODUCT NAME: AVANAFIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/841 20130613 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
